Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DNTH vs PVLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DNTH Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 4–3 Matrix Metrics)

DNTH Overall Winner 6-Pillar Tally: DNTH 3 – 1 PVLA (2 Tie) Matrix Metrics: DNTH 4 – 3 PVLA

As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). DNTH carries a Unified Composite Score of 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. 0.0% operating margin) and revenue trajectory (+205.6% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DNTH vs PVLA
DNTH NASDAQ Head-to-Head Winner
Dianthus Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$88.58
-3.52% 1D
Market Cap $5.2B
TTM Revenue $2.7M
Forward P/E N/M
Beta / 30D Vol 1.03β · 41% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 8.0 Fund 43.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $84.01 · SMA50: $88.08
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42

6-Pillar Scorecard Institutional Category Breakdown (DNTH 3 – 1 PVLA)

Columns: Metric · DNTH · PVLA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale DNTH
Revenue Growth (YoY) +205.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.7M N/A
Market Cap $5.2B $2.2B
3. Profitability & Quality DNTH
Gross Margin 100.0% N/A
Operating Margin -8683.9% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -22.6% -63.4%
4. Balance Sheet & Cash Flow PVLA
Cash Generation (TTM) -$176M -$43M
Cash Flow Margin N/A N/A
Net Cash / Leverage $54M Net Cash $193M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DNTH
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 83.5% (7th %ile) 47.9% (2nd %ile)
Put/Call OI Skew N/A 3.82x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DNTH (4) vs PVLA (3)
Institutional Metric DNTH PVLA Criterion Row Edge
Market Capitalization
Scale
$5.2B $2.2B Larger Scale DNTH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+205.6% +0.0% Higher Growth DNTH
Operating Margin (TTM)
Profitability
-8683.9% 0.0% Higher Margin PVLA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-22.6% -63.4% Higher ROE DNTH
52-Week Range Position
Momentum
65% ($34–$118) 68% ($72–$180) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.03β · 41% Vol 1.66β · 75% Vol Lower Realized Risk DNTH
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 48.2 / 100 (HOLD) Higher Composite PVLA
Trailing 12M Revenue (USD)
Operating Scale
$2.7M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$176M ($54M Net Cash) -$43M ($193M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DNTH +2.31 pp
DNTH: +22.87% · PVLA: +20.56%
3M Horizon PVLA +19.76 pp
DNTH: -23.34% · PVLA: -3.58%
6M Horizon PVLA +32.11 pp
DNTH: +5.95% · PVLA: +38.06%
1Y Horizon DNTH +69.35 pp
DNTH: +149.51% · PVLA: +80.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DNTH Revenue PVLA Revenue DNTH Op. Margin PVLA Op. Margin Margin Leader
FY2018 N/A $30M N/A -113.1% PVLA
FY2019 N/A $40M N/A -62.2% PVLA
FY2020 N/A $30M N/A -115.7% PVLA
FY2021 N/A $30M N/A -165.0% PVLA
FY2022 N/A $30M N/A -167.8% PVLA
FY2023 $0M $40M -1704.7% -27.7% PVLA
FY2024 $10M N/A -1633.7% N/A DNTH
FY2025 $0M N/A -8739.3% N/A DNTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DNTH CONSOLIDATION
149d in phase · OBV ACCUMULATION
Current IV 83.5%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DNTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DNTH Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.2B market capitalization and -8683.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DNTH vs PVLA Key Questions & Quantitative Answers

As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). DNTH carries a Unified Composite Score of 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. 0.0% operating margin) and revenue trajectory (+205.6% vs. +0.0% YoY).

DNTH leads the Growth & Scale pillar: DNTH posts +205.6% YoY revenue growth and +0.0% YoY earnings growth on $2.7M TTM revenue (100.0% gross margin, -8683.9% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DNTH cumulative revenue shifted N/A while PVLA shifted +33.3%. In operating R&D and SG&A reinvestment, DNTH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.

DNTH and PVLA trade at balanced relative valuation multiples. DNTH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DNTH (-22.6% ROE) versus PVLA (-63.4% ROE) capital efficiency.

In options market volatility and institutional positioning, DNTH carries 83.5% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.03β · 41% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.